Newswise — In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, recently published in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.
In a proof of concept study, the researchers demonstrated that combining a PARP inhibitor with a DNA methyltransferase (DNMT) inhibitor delivered a one-two punch to non-small cell lung cancer tumors, which are normally not associated with mutations in BRCA genes. The research, conducted in mouse models and cell lines, outlines the mechanistic action of the combination. The DNMT inhibitor triggers an effect that mimics a BRCA mutation in the cancer cell so the cell responds to the lethal effects of the PARP inhibitor, which prevents repair of damage to a tumor cell’s DNA, triggering cell death.
“When combined, these agents cause interactions that significantly disrupt cancer cells' ability to survive DNA damage,” said study senior author, Feyruz V. Rassool, PhD, professor of radiation oncology at UMSOM. “Our findings could expand the use of PARP inhibitors beyond the minority of inherited cancers that it now treats.”
Those who inherit two copies of a normal BRCA gene enjoy protection from DNA damage that can cause healthy cells to turn malignant. Those who inherit a mutation in this gene, however, have a higher risk of breast and ovarian cancer (in women) and prostate cancer (in men). Researchers have previously demonstrated that tumors that share molecular features of BRCA-mutant tumors – those with so-called “BRCAness” – respond to PARP inhibitor drugs designed to target tumors that arise from BRCA mutations. This new study from UMSOM is the first to demonstrate that cells can be induced to have a BRCAness phenotype or gene expression that is not the result of a mutation by treating them with the DNA methyltransferase inhibitor drug.
DNMT inhibitors suppress DNA methylation, which leads to changes in gene expression that significantly interfere with cancer cell growth. They are FDA-approved for use in myelodysplastic syndromes (cancers of the bone marrow),but are not usually combined with PARP inhibitors. Stephen Baylin, MD, Chief of Cancer Biology at Johns Hopkins University School of Medicine and graduate student Michael Topper at Johns Hopkins University, key collaborators in this study, have expertise in the action of these drugs.
The researchers also found that the DNMT and PARP inhibitor combination prevented cancer cells from repairing the DNA damage caused by radiation, a common treatment for lung cancer. “We are very excited by the new finding because it explains the mechanistic action of this drug combination, which we found has a synergistic effect, and so works better than either drug alone,” said Rachel Abbotts, MD PhD, a postdoctoral fellow in the Department of Radiation Oncology who is the first author of the paper. “When we combined with radiation therapy, which is the standard treatment for lung cancer, we measured an even bigger effect.”
The researchers are now aiming to test this protocol in an early phase trial in patients with non-small cell lung cancer that will be conducted in coordination with the Marlene and Stewart Greenebaum Comprehensive Cancer Center. Two years ago, Dr. Rassool and her research team demonstrated that this novel drug combination worked to disrupt cancer cells in acute myeloid leukemia and they are now testing the protocol in a trial of cancer patients with AML. Early results suggesthat this drug combination is well tolerated.
“Finding a new paradigm to attack cancer cells is very exciting, especially when researchers can make use of drugs that are already on the market and have been well tested for efficacy and toxicity,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "We are committed to translational research, and this is excellent example of how we are able to move an important scientific discovery from the laboratory into the practice where it may potentially benefit patients."
The research, which builds on previous work by Dr. Rassool and Dr. Baylin, was funded by a number of grants, including Stand Up 2 Cancer's inaugural Laura Ziskin Prize in Translational Research – a $250,000 grant awarded to the two researchers in 2012. Ziskin, a Hollywood film producer who died of metastatic breast cancer, was a co-founder of Stand Up 2 Cancer, an initiative founded in 2008 by nine women in the entertainment industry to accelerate groundbreaking research and bring new treatments to patients as quickly as possible. Funding for this work has continued through the Van Andel Research Institute-SU2C.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $530 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
Available for logged-in reporters only